Ratings Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Real-time Estimate Cboe BZX Other stock markets 09:35:02 2024-07-03 am EDT			5-day change	1st Jan Change
7.105 ^USD	-0.07%		+4.56%	-11.35%

Jun. 21	Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	MT
Jun. 17	Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company does not generate enough profits, which is an alarming weak point.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAUSCH HEALTH COMPANIES INC.	-11.35%	2.61B	C+
ELI LILLY AND COMPANY	+55.55%	816B	C+
NOVO NORDISK A/S	+39.22%	634B	B
JOHNSON & JOHNSON	-6.83%	351B	C+
MERCK & CO., INC.	+17.15%	323B	B-
ABBVIE INC.	+7.09%	293B	C+
ASTRAZENECA PLC	+13.40%	238B	B+
ROCHE HOLDING AG	+0.98%	222B	A+
NOVARTIS AG	+13.42%	218B	B-
AMGEN INC.	+7.87%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes